These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11328719)

  • 1. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.
    Stjernschantz JW
    Invest Ophthalmol Vis Sci; 2001 May; 42(6):1134-45. PubMed ID: 11328719
    [No Abstract]   [Full Text] [Related]  

  • 2. Current status of prostaglandin therapy: latanoprost and unoprostone.
    Susanna R; Chew P; Kitazawa Y
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S97-104. PubMed ID: 12204705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
    Stjernschantz J; Selén G; Astin M; Resul B
    Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin analogs in the treatment of glaucoma.
    Hejkal TW; Camras CB
    Semin Ophthalmol; 1999 Sep; 14(3):114-23. PubMed ID: 10790575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy.
    Tsukamoto H; Yokoyama T; Okada K; Okada M; Mochizuki H; Mishima HK
    Acta Ophthalmol Scand; 2000 Oct; 78(5):604-5. PubMed ID: 11037926
    [No Abstract]   [Full Text] [Related]  

  • 6. [Glaucoma therapy with prostaglandin F2 alpha derivatives].
    Diestelhorst M
    Ophthalmologe; 1997 Oct; 94(10):754-69. PubMed ID: 9432248
    [No Abstract]   [Full Text] [Related]  

  • 7. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: the Proctor Lecture.
    Bito LZ
    Invest Ophthalmol Vis Sci; 2001 May; 42(6):1126-33. PubMed ID: 11328718
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacodynamics and pharmacokinetics of prostaglandins and their derivates in eye tissues].
    Szaliński MR; Turno-Krecicka A
    Klin Oczna; 2001; 103(4-6):203-5. PubMed ID: 11975019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative analysis of life quality in patients receiving beta-blockers and xalathane (latanoprost)].
    Tugushi OA; Shliapuzhnikova AV; Listopadova NA
    Vestn Oftalmol; 2005; 121(4):41-3. PubMed ID: 16223045
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of topical ophthalmic latanoprost on intraocular pressure in normal horses.
    Davidson HJ; Pinard CL; Keil SM; Brightman AH; Sargeant JM
    Vet Ther; 2002; 3(1):72-80. PubMed ID: 12050830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
    Nakajima T; Matsugi T; Goto W; Kageyama M; Mori N; Matsumura Y; Hara H
    Biol Pharm Bull; 2003 Dec; 26(12):1691-5. PubMed ID: 14646172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe darkening of a facial skin graft from latanoprost.
    Calladine D; Harrison RJ
    Arch Ophthalmol; 2007 Oct; 125(10):1427-8. PubMed ID: 17923558
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma.
    Maruyama K; Shirato S; Haneda M
    Jpn J Ophthalmol; 2005; 49(1):61-2. PubMed ID: 15692779
    [No Abstract]   [Full Text] [Related]  

  • 15. Timolol + latanoprost: new preparation. Last-resort eye drops.
    Prescrire Int; 2003 Oct; 12(67):173-4. PubMed ID: 14619889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of intraocular pressure after topical administration of prostaglandin analogs.
    Ness T; Funk J
    Arch Ophthalmol; 1999 Dec; 117(12):1646-7. PubMed ID: 10604672
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment.
    Stjernschantz J
    Exp Eye Res; 2004 Apr; 78(4):759-66. PubMed ID: 15037110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans.
    Camras CB
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():519-25. PubMed ID: 7732900
    [No Abstract]   [Full Text] [Related]  

  • 20. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit; latanoprost and herpes simplex keratitis.
    Camras CB
    Am J Ophthalmol; 2000 Feb; 129(2):271-2; author reply 272-3. PubMed ID: 10682992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.